[go: up one dir, main page]

WO2011058367A3 - Test de diagnostic pour prédire la sensibilité à un traitement par un inhibiteur de poly(adp-ribose) polymérase - Google Patents

Test de diagnostic pour prédire la sensibilité à un traitement par un inhibiteur de poly(adp-ribose) polymérase Download PDF

Info

Publication number
WO2011058367A3
WO2011058367A3 PCT/GB2010/051888 GB2010051888W WO2011058367A3 WO 2011058367 A3 WO2011058367 A3 WO 2011058367A3 GB 2010051888 W GB2010051888 W GB 2010051888W WO 2011058367 A3 WO2011058367 A3 WO 2011058367A3
Authority
WO
WIPO (PCT)
Prior art keywords
parp
treatment
adp
ribose
polymerase
Prior art date
Application number
PCT/GB2010/051888
Other languages
English (en)
Other versions
WO2011058367A2 (fr
Inventor
Jonathan Richard Dry
Christopher George Harbron
Darren Richard Hodgson
Alan Yin Kai Lau
Mark James O'connor
John Edward Prime
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Limited filed Critical Astrazeneca Ab
Publication of WO2011058367A2 publication Critical patent/WO2011058367A2/fr
Publication of WO2011058367A3 publication Critical patent/WO2011058367A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91142—Pentosyltransferases (2.4.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne d'une manière générale des procédés pour traiter un cancer et des procédés de prédiction de la sensibilité d'une cellule cancéreuse à un traitement thérapeutique. En particulier, l'invention concerne les identités de gènes (biomarqueurs) qui peuvent être utilisés pour identifier des populations de personnes souffrant d'un cancer ou des individus souffrant d'un cancer qui sont susceptibles d'une réponse favorable à un traitement par un inhibiteur de poly(ADP-ribose) polymérase (PARP).
PCT/GB2010/051888 2009-11-13 2010-11-11 Test de diagnostic pour prédire la sensibilité à un traitement par un inhibiteur de poly(adp-ribose) polymérase WO2011058367A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26093409P 2009-11-13 2009-11-13
US61/260,934 2009-11-13

Publications (2)

Publication Number Publication Date
WO2011058367A2 WO2011058367A2 (fr) 2011-05-19
WO2011058367A3 true WO2011058367A3 (fr) 2011-08-18

Family

ID=43500036

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/051888 WO2011058367A2 (fr) 2009-11-13 2010-11-11 Test de diagnostic pour prédire la sensibilité à un traitement par un inhibiteur de poly(adp-ribose) polymérase

Country Status (1)

Country Link
WO (1) WO2011058367A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9637798B2 (en) 2013-05-21 2017-05-02 Dignity Health Genetic signature of vulnerability to inhibitors of base excision repair (BER) in cancer

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807823C (fr) 2010-08-24 2023-02-07 The Brigham And Women's Hospital, Inc. Methodes de prediction d'une reponse anticancereuse
EP2710142B1 (fr) * 2011-05-18 2017-04-26 Centre National de la Recherche Scientifique (CNRS) Signature pour le diagnostic de l'agressivité et l'instabilité génétique du cancer
WO2013133876A1 (fr) * 2011-12-07 2013-09-12 The Regents Of The University Of California Biomarqueurs destinés à la prédiction de la réponse à une inhibition de parp dans le cancer du sein
WO2013130347A1 (fr) * 2012-02-23 2013-09-06 The Children's Hospital Corporation Méthodes de prédiction d'une réponse anticancéreuse
US9512486B2 (en) * 2012-08-06 2016-12-06 The Institute Of Cancer Research: Royal Cancer Hospital Materials, methods, and systems for treating cancer
WO2014138101A1 (fr) * 2013-03-04 2014-09-12 Board Of Regents, The University Of Texas System Signature génique pour prédire un cancer déficient pour la recombinaison homologue (rh)
WO2014205105A1 (fr) * 2013-06-19 2014-12-24 The Regents Of The University Of California Biomarqueurs de réponse à l'inhibition de poly(adp-ribose) polymérase (parp) dans un cancer
WO2015042570A1 (fr) 2013-09-23 2015-03-26 The University Of Chicago Procédés et compositions concernant une thérapie anticancéreuse au moyen d'agents endommageant l'adn
WO2015168544A1 (fr) * 2014-05-02 2015-11-05 Emory University Traitements sélectifs de chimiothérapie et méthodes de diagnostic associées à ceux-ci
US10823738B2 (en) * 2015-12-07 2020-11-03 George Mason Research Foundation, Inc. Methods for breast cancer treatment
HUE064978T2 (hu) 2016-06-29 2024-04-28 Tesaro Inc A petefészekrák kezelésének módszerei
US11447830B2 (en) 2017-03-03 2022-09-20 Board Of Regents, The University Of Texas System Gene signatures to predict drug response in cancer
US11596637B2 (en) 2017-04-10 2023-03-07 Sierra Oncology, Inc. CHK1 (SRA737)/PARPi combination methods of inhibiting tumor growth
CN111868265B (zh) * 2017-09-30 2024-03-26 浙江数问生物技术有限公司 Dna重组修复功能评分rds在癌症治疗中的用途
SG11202006147SA (en) * 2017-12-27 2020-07-29 Tesaro Inc Methods of treating cancer
AU2019270336B2 (en) * 2018-05-15 2025-06-26 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
US20210093730A1 (en) * 2019-10-01 2021-04-01 Immunomedics, Inc. Biomarkers for antibody-drug conjugate monotherapy or combination therapy
GB202103080D0 (en) * 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
CN114934120A (zh) * 2022-06-20 2022-08-23 柳州市人民医院 一种快速鉴定早期结直肠癌的环状rna标志物的应用及诊断试剂盒
JPWO2024009946A1 (fr) * 2022-07-08 2024-01-11

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1178414A (fr) 1978-02-08 1984-11-27 Toyo Boseki Kabushiki Kaisha (Trading Under The Name Of Toyobo Co., Ltd.) Materiau d'emballage etanche
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4727022A (en) 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
JPH0314319A (ja) 1989-06-13 1991-01-23 Anritsu Corp ラダー抵抗回路
US5464871A (en) 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6285701B1 (en) 1998-08-06 2001-09-04 Lambda Physik Ag Laser resonator for improving narrow band emission of an excimer laser
EE05006B1 (et) 1999-01-11 2008-04-15 Agouron Pharmaceuticals, Inc. Polü(ADP-riboos)polümeraaside tritsüklilised inhibiitorid ja neid sisaldavad farmatseutilised kompositsioonid
US6465448B1 (en) 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
WO2001021615A1 (fr) 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Dérivés de benzimidazole
TR200101499T1 (tr) 1999-09-28 2002-09-23 Basf Aktiengesellschaft Azepinoindol türevleri, hazırlanmaları ve kullanımları.
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
AU2001240542A1 (en) 2000-02-01 2001-08-14 Basf Aktiengesellschaft Heterocyclic compounds and their use as parp inhibitors
WO2001079184A1 (fr) 2000-04-18 2001-10-25 Sumitomo Pharmaceuticals Company, Limited Composes de piperazine substitues
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
DE10022925A1 (de) 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
AU2001264595A1 (en) 2000-05-19 2001-12-03 Guilford Pharmaceuticals Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
HU228960B1 (hu) 2000-10-30 2013-07-29 Kudos Pharm Ltd Ftalazinon-származékok
ITMI20002358A1 (it) 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
US6794141B2 (en) 2000-12-22 2004-09-21 Arcturus Bioscience, Inc. Nucleic acid amplification
JPWO2002068407A1 (ja) 2001-02-28 2004-06-24 山之内製薬株式会社 ベンゾイミダゾール化合物
US20040176361A1 (en) 2001-05-23 2004-09-09 Masakazu Fujio Fused heterocyclic compound and medicinal use thereof
WO2003007959A1 (fr) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Derives de quinoxaline ayant une action inhibitrice sur parp
AU2002358650A1 (en) 2001-12-14 2003-06-30 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
AUPR975601A0 (en) 2001-12-24 2002-01-31 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives
US7157452B2 (en) 2001-12-31 2007-01-02 Mgi Gp, Inc. Substituted 4,9-dihydrocyclopenta{imn}phenanthridine-5-ones derivatives thereof and their uses
NZ534712A (en) 2002-02-19 2006-11-30 Ono Pharmaceutical Co Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
AU2003252314A1 (en) 2002-08-09 2004-02-25 Kyorin Pharmaceutical Co., Ltd. 4-substituted quinazoline-8-carboxyamide derivative and pharmaceutically acceptable addition salt thereof
WO2004024694A1 (fr) 2002-09-10 2004-03-25 Kyorin Pharmaceutical Co., Ltd. Derive de 4-(aryle substitue)-5-hydroxyisoquinolinone
ATE540928T1 (de) 2002-11-22 2012-01-15 Mitsubishi Tanabe Pharma Corp Isochinolinverbindungen und ihre medizinische verwendung
BRPI0407757A (pt) 2003-02-28 2006-02-14 Inotek Pharmaceuticals Corp derivados de benzamida tetracìclica e métodos de uso dos mesmos
JP4027406B2 (ja) 2003-03-12 2007-12-26 クドス ファーマシューティカルズ リミテッド フタラジノン誘導体
JP2006522088A (ja) 2003-03-31 2006-09-28 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤の塩
HU0301154D0 (en) 2003-04-28 2003-07-28 Hideg Kalman Dr Pharmaceutical composition
HU227948B1 (en) 2003-04-30 2012-07-30 Pecsi Tudomanyegyetem Quinazoline derivatives and their use for the preparation of pharmaceutical compositions inhibiting parp enzyme
ES2396334T3 (es) 2003-05-28 2013-02-20 Eisai Inc. Compuestos, métodos y composiciones farmacéuticas para la inhibición de PARP
WO2004108723A1 (fr) 2003-06-04 2004-12-16 Altana Pharma Ag 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones utilisees comme inhibiteurs de parp
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
ES2339663T3 (es) 2003-07-25 2010-05-24 Cancer Research Technology Limited Inhibidores de parp triciclicos.
BRPI0414136A (pt) 2003-09-04 2006-10-31 Aventis Pharma Inc indóis substituìdos como inibidores de poli(adp-ribose) polimerase (parp)
WO2005054209A1 (fr) 2003-11-20 2005-06-16 Janssen Pharmaceutica N.V. 2-quinolinones et 2 quinoxalinones a substitution 7-phenylalkyl tenant lieu d'inhibiteurs de poly(adp-ribose) polymerase inhibitors
AU2004295058B9 (en) 2003-11-20 2011-06-30 Janssen Pharmaceutica N.V. 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
CA2547077C (fr) 2003-12-01 2015-11-03 Kudos Pharmaceuticals Limited Inhibiteurs de reparation d'adn endommage pour le traitement du cancer
AU2004295059B2 (en) 2003-12-05 2010-12-16 Janssen Pharmaceutica N.V. 6-substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
US7652014B2 (en) 2003-12-10 2010-01-26 Janssen Pharmaceutica Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
DE102004028973A1 (de) 2004-06-16 2006-01-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
EA011552B1 (ru) 2004-06-30 2009-04-28 Янссен Фармацевтика Н.В. Производные хиназолиндиона в качестве ингибиторов parp
AU2005259189B2 (en) 2004-06-30 2011-04-21 Janssen Pharmaceutica N.V. Phthalazine derivatives as PARP inhibitors
JP4836946B2 (ja) 2004-06-30 2011-12-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐ阻害剤としての置換２−アルキルキナゾリノン誘導体
WO2006024545A1 (fr) 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Composes bicycliques naturels condenses et utilisation de ceux-ci comme inhibiteurs de parp et des processus inflammatoires a mediation parp
DE102004050196A1 (de) 2004-10-15 2006-04-20 Sanofi-Aventis Deutschland Gmbh Substituierte 2-Pyridon-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
US20060204981A1 (en) 2005-01-07 2006-09-14 Chiang Li Compositions for modulation of PARP and methods for screening for same
MX2007008771A (es) 2005-01-19 2007-09-11 Mgi Gp Inc Compuestos de diazabenzo [des] antracen-3-ona y metodos para inhibir parp.
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
WO2008147418A1 (fr) 2006-06-12 2008-12-04 Bipar Sciences, Inc. Procédé permettant de traiter des maladies avec des inhibiteurs de parp
US20080262062A1 (en) 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
PL2336120T3 (pl) 2007-01-10 2014-12-31 Msd Italia Srl Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP)
TW200900396A (en) 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
US20090023727A1 (en) 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
WO2009121031A1 (fr) 2008-03-27 2009-10-01 Vascular Biosciences, Inc. Procédé d'identification de nouveaux candidats thérapeutiques via l'analyse d'expression génique dans les maladies d'origine vasculaire

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ALMEIDA ET AL: "A unified view of base excision repair: Lesion-dependent protein complexes regulated by post-translational modification", DNA REPAIR, vol. 6, no. 6, 3 May 2007 (2007-05-03), ELSEVIER, AMSTERDAM, NL, pages 695 - 711, XP022059296, ISSN: 1568-7864, DOI: 10.1016/J.DNAREP.2007.01.009 *
ANONYMUS: "PARP Inhibitors (future cancer therapy) and the importance of molecular pathology", 16 September 2009 (2009-09-16), XP002620580, Retrieved from the Internet <URL:www.innovationandchoice.com/2009/09/16/parp-inhibitors-future-cancer-therapy-and-the-importance-of-molecular-pathology> [retrieved on 20110202] *
BRUCE JAMES W ET AL: "The host cell sulfonation pathway contributes to retroviral infection at a step coincident with provirus establishment.", PLOS PATHOGENS, vol. 4, no. 11, E1000207, November 2008 (2008-11-01), pages 1 - 15, XP002620581, ISSN: 1553-7374 *
DAMIA ET AL: "Targeting DNA repair as a promising approach in cancer therapy", EUROPEAN JOURNAL OF CANCER, vol. 43, no. 12, 11 August 2007 (2007-08-11), PERGAMON PRESS, OXFORD, GB, pages 1791 - 1801, XP022196531, ISSN: 0959-8049, DOI: 10.1016/J.EJCA.2007.05.003 *
DRY JONATHAN R ET AL: "Identifying pre-clinical predictive biomarkers for the PARP inhibitor olaparib", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 51, 21 April 2010 (2010-04-21), AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, pages 848 - 849, XP009143942, ISSN: 0197-016X *
LORD C J ET AL: "A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity", DNA REPAIR, vol. 7, no. 12, 1 December 2008 (2008-12-01), ELSEVIER, AMSTERDAM, NL, pages 2010 - 2019, XP025627852, ISSN: 1568-7864, [retrieved on 20081015], DOI: 10.1016/J.DNAREP.2008.08.014 *
MCCABE NUALA ET AL: "Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition", CANCER RESEARCH, vol. 66, no. 16, 15 August 2006 (2006-08-15), AMERICAN ASSOCIATION FOR CANCER REREARCH, US, pages 8109 - 8115, XP002482543, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-06-0140 *
PERALTA-LEAL A ET AL: "PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases", FREE RADICAL BIOLOGY AND MEDICINE, vol. 47, no. 1, 1 July 2009 (2009-07-01), ELSEVIER SCIENCE, US, pages 13 - 26, XP026158945, ISSN: 0891-5849, [retrieved on 20090410], DOI: 10.1016/J.FREERADBIOMED.2009.04.008 *
TURNER NICHOLAS C ET AL: "A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor", EMBO JOURNAL, vol. 27, no. 9, 1 May 2008 (2008-05-01), OXFORD UNIVERSITY PRESS, SURREY, GB, pages 1368 - 1377, XP002498071, ISSN: 0261-4189, [retrieved on 20080403], DOI: 10.1038/EMBOJ.2008.61 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9637798B2 (en) 2013-05-21 2017-05-02 Dignity Health Genetic signature of vulnerability to inhibitors of base excision repair (BER) in cancer

Also Published As

Publication number Publication date
WO2011058367A2 (fr) 2011-05-19

Similar Documents

Publication Publication Date Title
WO2011058367A3 (fr) Test de diagnostic pour prédire la sensibilité à un traitement par un inhibiteur de poly(adp-ribose) polymérase
NZ620799A (en) Molecular diagnostic test for cancer
MX2009002936A (es) Biomarcadores de la modulacion de objetivo, eficacia, diagnostico, y/o pronostico para los inhibidores de raf.
EP2474626A3 (fr) Détection de néoplasme à partir d&#39;un échantillon de selles
EP2260109A4 (fr) Procédés et compositions à base de micro-arn permettant de diagnostiquer, de pronostiquer et de traiter des troubles liés à la prostate
WO2006135886A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer
WO2011160063A3 (fr) Procédés et matériaux pour évaluer la perte d&#39;hétérozygotie
EP2527466A3 (fr) Variants génétiques du CHR2 utilisés comme marqueurs dans l&#39;évaluation, le diagnostic, le pronostic et le traitement d&#39;un risque de cancer du sein
EP2385062A3 (fr) Procédés et compositions pour le traitement du cancer de la prostate ou pour l&#39;induction d&#39;une réponse immunitaire humorale contre le cancer de la prostate
WO2011047033A3 (fr) Biomarqueur d&#39;identification de cellules tumorales de mélanome
EP2003196A3 (fr) Compositions et procédés de diagnostic et de traitement des cancers
WO2006138275A3 (fr) Compositions et procedes de traitement et de diagnostic de cancer
HK1199068A1 (en) Identification of gene expression profile as a predictive biomarker for lkb1 status
EP2618146A3 (fr) Sélection d&#39;un médicament pour la thérapie du cancer du sein à partir des matrices d&#39;anticorps
WO2010045318A3 (fr) Cibles géniques et protéiques exprimées par des gènes représentant des profils de biomarqueurs et des jeux de signatures par type de tumeurs
EP3211094A3 (fr) Procédés pour traiter, diagnostiquer, et surveiller la polyarthrite rhumatoïde
MX350723B (es) Proteínas de unión a il-1.
MX2011009690A (es) Métodos y composiciones para trastornos relacionados con la proliferación celurar.
WO2007027509A3 (fr) Evaluation et traitement de la sclerodermie
WO2007093657A3 (fr) Procédé destiné au diagnostic moléculaire du cancer de la prostate et nécessaire destiné à mettre en oeuvre ce procédé
EA200801046A1 (ru) Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro
WO2008091814A3 (fr) Évaluation de l&#39;asthme et d&#39;une expression d&#39;un gène dépendant d&#39;un allergène
WO2008109423A8 (fr) Dosage multigène pour prédire les résultats de traitement concernant un individu atteint de glioblastome
WO2010051314A3 (fr) Classification génomique de carcinomes pulmonaires non à petites cellules en fonction de profils d&#39;altérations du nombre de copies de gènes
NZ589251A (en) Novel marker for detection of bladder cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10782357

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10782357

Country of ref document: EP

Kind code of ref document: A2